Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Australia’s Sigma Blocked From Marketing Effexor Generic

This article was originally published in PharmAsia News

Executive Summary

Sigma Pharmaceuticals of Australia lost a case in federal court in its attempt to market a generic version of U.S.-based Wyeth's antidepressant Effexor (venlafaxine). The court issued an injunction against Sigma marketing the drug until the validity of Wyeth's patent for Effexor is determined later this year in another court. Sigma already had begun importing its generic copy, Evelexa, and had been contacting possible customers about a drug it expected to deliver as early as June 1. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts